Free tool
FAERS Monitor: Xifaxan
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021361 or its brand name (Xifaxan, Rifaximin). Reports on generic versions are filed under their own applications.
Reports
21,335
Serious
16,688
78% of reports
Hospitalization
8,408
Death reported
6,241
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death4,264
- hospitalisation1,954
- diarrhoea1,258
- off label use1,176
- therapy interrupted1,176
- ammonia increased862
- nausea854
- hepatic encephalopathy836
- fatigue815
- drug ineffective752
- confusional state733
- insurance issue729
- hepatic cirrhosis708
- inability to afford medication707
- condition aggravated669
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 11 |
| 2005 | 42 |
| 2006 | 71 |
| 2007 | 48 |
| 2008 | 31 |
| 2009 | 46 |
| 2010 | 81 |
| 2011 | 115 |
| 2012 | 177 |
| 2013 | 186 |
| 2014 | 294 |
| 2015 | 904 |
| 2016 | 1,653 |
| 2017 | 2,331 |
| 2018 | 1,477 |
| 2019 | 1,813 |
| 2020 | 1,958 |
| 2021 | 1,931 |
| 2022 | 1,771 |
| 2023 | 2,023 |
| 2024 | 1,640 |
| 2025 | 1,328 |
| 2026 | 1,404 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,032,824 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ammonia increasedSignal | 862 | 200.2 | 186.3 | 141,874 |
| hepatic encephalopathySignal | 836 | 96.9 | 90.4 | 72,199 |
| inability to afford medicationSignal | 707 | 75.5 | 70.0 | 48,218 |
| insurance issueSignal | 729 | 49.3 | 45.8 | 32,830 |
| hepatic cirrhosisSignal | 708 | 38.6 | 35.8 | 24,925 |
| therapy interruptedSignal | 1,176 | 16.5 | 15.6 | 16,857 |
| hospitalisationSignal | 1,954 | 12.7 | 12.2 | 20,908 |
| deathSignal | 4,264 | 4.9 | 4.8 | 13,723 |
| confusional stateSignal | 733 | 4.5 | 4.2 | 1,990 |
| condition aggravatedSignal | 669 | 2.2 | 2.0 | 427 |
| diarrhoea | 1,258 | 1.9 | 1.8 | 573 |
| off label use | 1,176 | 1.3 | 1.3 | 97 |
| nausea | 854 | 1.1 | 1.0 | 3 |
| fatigue | 815 | 1.0 | 1.0 | 1 |
| drug ineffective | 752 | 0.6 | 0.5 | 273 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.